TP53BP1 and ovarian cancer: We also used BRCA1-deficient ovarian cancer cell line UWB1 75,76 and showed that acquired Olaparib resistance of UWB1 cells upon 53BP1 depletion can be reverted by inhibiting PIF1 (Supplementary Figure 11b).